Vizsgálati helyszín
Medical Center Teodora EOOD
Ruse, 7000, BulgáriaEU-13 felzárkózó országMég nincs intézményhez kötve
- 14futó vizsgálat
- 6lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 20 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis14 vizsgálat
- 2. fázis5 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz7 vizsgálat
- Lezárult6 vizsgálat
- Toboroz4 vizsgálat
- Még nem toboroz3 vizsgálat
- Fő szponzor
- Janssen Research & Development, LLC3 vizsgálat
- MoonLake Immunotherapeutics AG3 vizsgálat
- AbbVie2 vizsgálat
- AstraZeneca2 vizsgálat
- Acelyrin Inc.1 vizsgálat
- és még 9
Futó vizsgálatok
Még nem toboroz
A Trial of LAD603 in Patients with Systemic Lupus Erythematosus
2026-527200-24-00· 2. fázis· Almirall S.A.· Forrás
Toboroz
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135· 3. fázis· AstraZeneca· Forrás
Toboroz
SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures
2025-520587-18-00· 2. fázis· Supernus Pharmaceuticals Inc.· Forrás
Még nem toboroz
A study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate response to methotrexate and tumor necrosis factor inhibition (START SYNERGY)
2025-524005-32-00· 2. fázis· Elevara Medicines Limited· Forrás
Még nem toboroz
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.
2024-516219-25-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Toboroz
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462· 2. fázis· Immunovant Sciences GmbH· Forrás
Toboroz
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
2023-504022-19-01· 3. fázis· AstraZeneca AB· Forrás
Fut, nem toboroz
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098· 3. fázis· Janssen Research & Development, LLC· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in rheumatoid arthritis
2024-510826-16-00· 3. fázis· Mabxience Research S.L.· Forrás
Lezárult
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.
2024-514981-37-00· 2. fázis· Synact Pharma ApS· Forrás
Lezárult
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
NCT06624228· 3. fázis· UCB Biopharma SRL· Forrás
Lezárult
A study to test if izokibep improves psoriatic arthritis symptoms and to see how safe izokibep is
2022-501362-22-00· 2/3. fázis· Acelyrin Inc.· Forrás
Fut, nem toboroz
A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis
NCT05785611· 3. fázis· Alfasigma S.p.A.· Forrás
Lezárult
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
NCT04169373· 3. fázis· AbbVie· Forrás
Hibát jelzek